Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neonatal Stand-Alone Screening Kit For Metabolic Disorders Cleared By FDA

This article was originally published in The Gray Sheet

Executive Summary

PerkinElmer will market its NeoGram amino acids and acylcarnitines tandem mass spectrometry (TMS) kit as a cost-effective alternative to laboratory blood testing for individual defects of metabolism among newborns

You may also be interested in...



National Newborn Screening Program Could Benefit States, Be Cost-Effective

A nationally-mandated newborn screening program for 29 heritable diseases could benefit individual states, according to an FDL-1HHS advisory panel report released March 8 in the Federal Register

National Newborn Screening Program Could Benefit States, Be Cost-Effective

A nationally-mandated newborn screening program for 29 heritable diseases could benefit individual states, according to an FDL-1HHS advisory panel report released March 8 in the Federal Register

HHS Heritable Disease Panel To Recommend Core Newborn Screening Menu

Recommendations on the minimum requirements that states should set for newborn screening of heritable disorders will be formalized at a Health Resources & Services Administration meeting Sept. 22-23

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel